Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news


PBAC sets scene for MS battle

Posted 19 October 2020

BMS' new multiple sclerosis treatment Zeposia has been recommended for PBS listing, setting the stage for a head-to-head market battle with Novartis.

The drug was presented to the PBAC in March but held over awaiting regulatory finalisation, which came in late July, however the reimbursement committee only revealed late Friday that it had given a green light to the listing.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Special Report
Aust Covid Vaccine Tracker
UPDATES: UNICEF stockpiling one billion syringes
Approvals Action
Shakeup for insulin
New biosim plus hypertension and herpes generics
Top of the Hill
Avoiding the Emperor's mistake
Not everyone is convinced about industry's budget win